Table 1.

Calculated IC₅₀ and IC₉₀ for λ-carrageenan, cellulose sulfate, and dextran sulfate (mg/mL)

	P4-R5 MAGI				Human PBMCs
	HIV-1 BaL		HIV-1 IIIB		HIV-1 BaL		HIV-1 IIIB
	IC50	IC90	IC50	IC90	IC50	IC90	IC50	IC90
LC	0.0037 (± 0.0009)	6.04a (± 0.79)	0.064 (± 0.0084)	1.96 (± 0.077)	0.967 (± 0.53)	3.16b (± 0.04)	0.061 (± 0.021)	0.87 (± 0.32)
CS	0.023 (± 0.0018)	1.24 (± 0.47)	0.003 (± 0.00047)	0.026 (± 0.00073)	0.0026 (± 0.0003)	0.0091 (± 0.0052)	0.014 (± 0.0034)	0.03 (± 0.0025)
DS	0.0058 (± 0.0011)	0.031 (± 0.012)	0.00052 (± 0.00011)	0.0028 (± 0.00015)	0.14 (± 0.045)	0.9 (± 0.18)	0.00056 (± 0.00017)	0.014 (± 0.0064)

CS cellulose sulfate, DS dextran sulfate, IC₅₀ the concentration at which 50% virus inhibition is achieved, IC₉₀ the concentration at which 90% virus inhibition is achieved, LC λ-carrageenan, PBMCs peripheral blood mononuclear cells

^aExtrapolated concentration

^bLC concentrations > 3.16 mg/mL could not be used due to excessive solution viscosity. Because 90% inhibition of HIV-1 BaL infection by LC in PBMCs was not achieved, the LC IC₇₅ (concentration that resulted in a 75% reduction of infection with respect to mock-treated, HIV-1-infected cells) was calculated and used in the PBMC washout experiments

Presented data are from two independent experiments in which each data point was examined in triplicate